Inhalation Sciences receives IRS order worth over 914,000 SEK from new US pharma customer

Report this content

Inhalation Sciences AB (ISAB) has received an order worth over 914,000 SEK (81,200 Euros) for an Inhalation Research Service (IRS) project from a new US customer developing targeted antiviral therapies. In this first project they have chosen to use the DissolvIt® module to carry out dissolution testing, due to its exceptional accuracy which can reduce risk and attrition in later drug development.

ISAB has received an order from a new customer, a cutting-edge US pharmaceutical company developing novel antiviral therapies to treat a range of viral diseases from influenza to COVID-19. Initially the new customer will carry out in vitro dissolution testing using DissolvIt®, ISAB’s leading in vitro dissolution and absorption testing module.

DissolvIt® is one of a wide range of high-precision exposure modules that can connect to ISAB’s central aerosol generation system PreciseInhale®. By using a unique “precision dosing” methodology, PreciseInhale® can generate the same aerosol across exposure modules that include in vivo, lungs ex vivo, and in vitro exposure and dissolution testing (DissolvIt®).

ISAB CEO Manoush Masarrat: “We are delighted to welcome this new customer and look forward to starting our collaboration with them. We are confident that the quality of our expertise and data will in turn help them to make the best possible decisions about their products’ development moving forward.”


Explore DissolvIt’s capabilities here. 

Read ISAB’s publications on DissolvIt® here.

Explore PreciseInhale’s range of exposure modules here.

Explore Inhalation Research Services here

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO


Mobile: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.

The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on 31 January 2023.



Documents & Links